drugset / Trial / NCT00728481

The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis

NCT00728481

Phase 2/3 Completed 51 enrolled Mayo Clinic AstraZeneca · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The primary aim of this study was to determine the proportion of patients with esophageal eosinophilic infiltration that have objective (measurable) evidence of gastroesophageal reflux disease (GERD). This study was also done to see if patients that have eosinophilic esophagitis (EE) and GERD would receive relief from taking the medication Nexium or a steroid called Pulmicort. The study also evaluated the accuracy of pH monitoring (acid exposure) within the esophagus as a predictor of endoscopic, histological and symptomatic response in patients with EE.

Timeline

Start
2008-05
Primary completion
2010-12
Completion
2010-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Budesonide Small molecule 1 g Oral
Comparator Esomeprazole Small molecule 40 mg Oral